TELA Bio Announces Publication of 24-Month BRAVO Study Results Demonstrating Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repair
October 26, 2022 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., Oct. 26, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical...
TELA Bio to Participate in Upcoming Investor Conferences
September 01, 2022 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio to Participate in Inaugural Gilmartin Group Emerging Growth Company Showcase
August 23, 2022 16:01 ET
|
TELA Bio, Inc.
MALVERN, Pa., Aug. 23, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares
August 18, 2022 16:01 ET
|
TELA Bio, Inc.
MALVERN, Pa., Aug. 18, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio Announces Pricing of Public Offering of Common Stock
August 15, 2022 22:20 ET
|
TELA Bio, Inc.
MALVERN, Pa., Aug. 15, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio Announces Proposed Public Offering of Common Stock
August 15, 2022 16:01 ET
|
TELA Bio, Inc.
MALVERN, Pa., Aug. 15, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio Reports Second Quarter 2022 Financial Results
August 10, 2022 16:01 ET
|
TELA Bio, Inc.
MALVERN, Pa., Aug. 10, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio to Participate in Upcoming Investor Conferences
August 05, 2022 07:00 ET
|
TELA Bio, Inc.
MALVERN, Pa., Aug. 05, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that...
TELA Bio Highlights Results from BRAVO and ReBAR Studies on the Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repairs; Data to Be Presented at 2022 American Hernia Society (AHS) Meeting
August 04, 2022 07:00 ET
|
TELA Bio, Inc.
24-Month BRAVO study results showed a 2.6% recurrence rate in diverse clinical scenarios Robotic Reinforced Biologic Augmented Repair (ReBAR) study showed a 1.9% recurrence rate at two-year mark ...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 29, 2022 16:01 ET
|
TELA Bio, Inc.
MALVERN, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction...